Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Boehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

12 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Eli Lilly and Company and Boehringer Ingelheim today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

11 Jan 2011

All fat cells not the same

All fat cells are not the same - a fact that has implications in the understanding and treatment of type 2 diabetes and obesity, said researchers from Baylor College of Medicine (www.bcm.edu) in a report that appears in the current issue of the Journal of Cell Biology (http://www.jcb.rupress.org/).

10 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

A simpler form of testing individuals with risk factors for diabetes could improve diabetes prevention efforts by substantially increasing the number of individuals who complete testing and learn whether or not they are likely to develop diabetes.

7 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Diet low in micronutrients can contribute to metabolic syndrome

Results of an epidemiological study conducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and the Corporacion Ecuatoriana de Biotecnologia showed that the metabolic syndrome, a condition that increases a person's risk of developing cardiovascular disease and type 2 diabetes, was prevalent in a low-income urban community in Ecuador and that a poor diet low in micronutrients appeared to contribute.

5 Jan 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

Depression and diabetes linked to increased risk of death from heart disease in women

Depression and diabetes appear to be associated with a significantly increased risk of death from heart disease and risk of death from all causes over a six-year period for women, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Jan 2011

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.

29 Dec 2010

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

28 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

24 Dec 2010

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) for the expanded use of BYETTA® (exenatide) injection as an add-on therapy to basal insulin, with or without metformin and/or a thiazolidinedione (TZD) in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.

23 Dec 2010

Excessive carbohydrates, rather than fat, may be the source of America's dietary woes

A growing number of top nutritional scientists are pointing to excessive carbohydrates, rather than fat, as the source of America's dietary woes. As reported in the Los Angeles Times on December 20, some researchers are saying that cutting carbohydrates is the key to reversing obesity, heart disease, Type 2 diabetes and hypertension.

22 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

All fat cells not the same

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

GLUMETZA tablets are now available to wholesalers and physicians

Diet low in micronutrients can contribute to metabolic syndrome

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

Depression and diabetes linked to increased risk of death from heart disease in women

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

AMPK activates autophagy by activating ATG1 enzyme

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Excessive carbohydrates, rather than fat, may be the source of America's dietary woes

Top ten advances in cardiovascular, stroke research in 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in